2025-05-03
Genenet Technology is a UK-based pioneering company focused on advanced organoid and genetic circuit engineering, powered by AI and quantum technology. Focusing on revolutionizing the field of preclinical drug discovery, Genenet Technology established their “One for ALL” platform to redefine OOC technology and establish the foundation for a one-step, multi-organoid-onchip system to support clients from the organoid formation to the drug screening. Their innovations have earned them the position as the winner of the IC Taiwan Grand Challenge (ICTGC) Batch 2 in the Smart Medtech category.
AI Plays a Pivotal Role in Developing Novel Medication
According to a Drug Discovery Today article published in 2022, AI has significant potential in the drug discovery and development value chain. This can span from target identification to clinical development. The article shared that conventional drug discovery is typically long, complex, and high-risk, with an average process time of 10 to 15 years and costs up to USD 2.8 billion on average, with a failure rate of 80 to 90%. To mitigate this trend, major companies have invested in AI to improve the success rate, especially from target identification through to preclinical development. Whether to identify targets with a strong link to disease, create tractable drug targets, optimize the drug, or perform any other function, AI now plays a significant role in the drug discovery process.
Introducing IC Taiwan Grand Challenge
To boost Taiwan’s position as a global semiconductor powerhouse, the National Science and Technology Council (NSTC) organizes the IC Taiwan Grand Challenge. Focusing on teams actively leveraging innovative IC design to develop advanced application solutions or enhanced technologies, the ICTGC puts special attention to teams in the fields of AI Core technologies and Chips, Smart Mobility, Smart Manufacturing, Smart Medtech, and Sustainability. Genenet was selected as a winner in the Smart Medtech category with their innovative patented technology – Quantum-Powered Organoid-on-a-Chip Systems.
Quantum-Powered Organoid-on-a-Chip Systems Optimize Drug Discovery Process
Founded in 2021, Genenet Technology pioneers a revolutionary approach combining organ-on-chip technology, quantum simulation, synthetic genetic circuit design, and AI single-cell sequencing data analysis to transform drug discovery and biomedical manufacturing. Their Quantum-Powered Organoid-on-a-Chip Systems offer improvements over the industry standards for drug screening to mitigate the existing issues of high drug discovery failure rates. By providing an enhanced understanding of organoid biology and quantum application in drug-induced toxicity prediction to target gene/pathway candidates for validation engineering.
Compared with traditional Organoid-on-a-Chip (OOC), their solutions will help save time and money. The application of electrical stimulation with quantum-based real-time monitoring systems for multi-organoid models provides closer proximity to humans, supporting the multi-organoid formation and culturing and toxicity analysis in complex models. Their solutions will solve the issues of lower physiological relevance, as well as difficult and expensive to replicate organoid experiments.
Genenet’s patented technology is designed for broad application across medicine, synthetic biology, and pharmaceutical research; providing genetic circuit design services, R&D consultation, and patent licensing for academic and industry partners. They have secured major international grants, including Innovate UK, the British Office in Taipei, CPI, Medicines Discovery Catapult, and ITRI Taiwan, with 3 international patents across key markets in the US, UK, and EU.
Keen to meet the winners?
Unveil Event Open to Register!
- DATE: 5/22(Thur.) 13:00-15:00
- VENUE: Taipei Nangang Exhibition Center (TaiNEX) Halls 2 4F, Pi Stage at InnoVEX
- REGISTER NOW: https://lihi2.com/LBl8Q
